Responsible for identifying and clinically validating through proof-of-concept new indications for Pfizer development compounds. Explored and implemented novel approaches to collaboration across government, foundation, academic, and pharmaceutic sectors supporting more effective and efficient drug development.

Provided scientific and managerial leadership for Joint Biology, Pulmonary Immunology, and Biochemical Pharmacology groups.

Created Biochemical Pharmacology group responsible for conducting primary plate-based potency/selectivity assays using highly-automated assay technologies.

Program leader for molecular target with therapeutic potential in Cardiovascular, Arthritis, Oncology, and Ophthalmology areas. Defined multi-project research strategy for DMOAD portfolio.

Project leader responsible for all aspects of team leadership for novel arthritis therapeutic, including defining strategy, tactics, communicating progress, and engaging cross-functional teams.

Responsible for establishing a cross-sector team of scientific and business expertise that resulted in the successful outlicensing of a COX-2 inhibitor for veterinary use.

Project leader for team advancing a novel therapeutic for asthma based on inhibition of LTC4S and individual contributor to anti-inflammatory project based on inhibition of fatty acid desaturase.

Responsible for purification and characterization of recombinant tissue factor pathway inhibitor as a novel anti-sepsis agent.

Characterized aspartyl b-hydoxylase and the role of this post-translational modification in vitamin K-dependent protiens.